Equities Analysts Set Expectations for Harrow Q3 Earnings

Key Points

• B. Riley analysts have raised their Q3 2025 earnings per share (EPS) estimate for Harrow, Inc. from $0.25 to $0.29.
• Harrow has received multiple upgrades from analysts, with a consensus rating of "Buy" and an average target price of $64.67.
• Shares of Harrow opened at $38.16 and have shown significant institutional interest, with 72.76% of the company's stock owned by institutional investors.

Harrow, Inc. (NASDAQ:HROW - Free Report) - Analysts at B. Riley boosted their Q3 2025 earnings per share estimates for shares of Harrow in a research note issued to investors on Thursday, August 21st. B. Riley analyst M. Mamtani now forecasts that the company will post earnings per share of $0.29 for the quarter, up from their prior estimate of $0.25. The consensus estimate for Harrow's current full-year earnings is ($0.53) per share. B. Riley also issued estimates for Harrow's Q4 2025 earnings at $0.65 EPS and FY2027 earnings at $4.21 EPS.

Other analysts have also recently issued research reports about the company. HC Wainwright lifted their price target on Harrow from $60.00 to $64.00 and gave the company a "buy" rating in a report on Wednesday, August 13th. William Blair initiated coverage on Harrow in a report on Tuesday, June 10th. They issued an "outperform" rating for the company. Zacks Research raised Harrow from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 14th. BTIG Research lifted their price objective on Harrow from $62.00 to $63.00 and gave the company a "buy" rating in a research note on Thursday, August 14th. Finally, Cantor Fitzgerald initiated coverage on Harrow in a research note on Friday, July 11th. They issued an "overweight" rating and a $76.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $64.67.

Harrow Trading Up 2.5%

HROW traded up $0.96 during midday trading on Friday, hitting $39.12. The company's stock had a trading volume of 618,433 shares, compared to its average volume of 674,553. The company has a current ratio of 0.62, a quick ratio of 0.58 and a debt-to-equity ratio of 0.78. The firm has a market cap of $1.45 billion, a P/E ratio of -156.48 and a beta of 0.41. The firm has a 50-day moving average price of $33.93 and a two-hundred day moving average price of $29.14. Harrow has a 52-week low of $20.85 and a 52-week high of $59.23.

Harrow (NASDAQ:HROW - Get Free Report) last posted its quarterly earnings results on Monday, August 11th. The company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.01 by $0.23. The company had revenue of $63.74 million during the quarter, compared to analysts' expectations of $64.23 million. Harrow had a negative return on equity of 2.18% and a negative net margin of 4.49%. Harrow has set its FY 2025 guidance at EPS.

Hedge Funds Weigh In On Harrow

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC lifted its position in Harrow by 345.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,373 shares of the company's stock worth $103,000 after acquiring an additional 2,615 shares in the last quarter. Engineers Gate Manager LP lifted its position in Harrow by 194.7% during the 2nd quarter. Engineers Gate Manager LP now owns 35,565 shares of the company's stock worth $1,086,000 after acquiring an additional 23,495 shares in the last quarter. Bank of America Corp DE lifted its position in Harrow by 266.8% during the 2nd quarter. Bank of America Corp DE now owns 213,448 shares of the company's stock worth $6,519,000 after acquiring an additional 155,258 shares in the last quarter. Raymond James Financial Inc. acquired a new position in Harrow during the 2nd quarter worth approximately $48,000. Finally, The Manufacturers Life Insurance Company lifted its position in Harrow by 2.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 16,547 shares of the company's stock worth $505,000 after acquiring an additional 341 shares in the last quarter. 72.76% of the stock is owned by institutional investors and hedge funds.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.